VIVE — Vivesto AB Share News
0.000.00%
Last trade - 00:00- SEK95.10m
- SEK63.62m
Australia's Kazia Therapeutics gains on license deal with Swedish firm
Brief: Oasmia Buys Global Development And Commercialization Rights For Cantrixil
Brief: Oasmia Pharmaceutical Q3 Oper Loss Narrows To SEK 28.6 Mln
Brief: Oasmia Secures IP Rights In Australia And Brazil
Brief: Oasmia’s Partner Signs Licensing Deal For Commercialization Of Apealea in Europe
Brief: Oasmia Q2 Operating Loss Widens To SEK 53.7 Mln
Brief: Oasmia’s Partner Elevar Provides Update On Apealea Development Plans In Ovarian Cancer
Brief: Oasmia Pharmaceutical Appoints Robert Maiorana As Acting CFO
Brief: Oasmia Says Xmena Patent Approved In India And Soon In Australia
Brief: The Disciplinary Committee Of Nasdaq Stockholm Orders Oasmia Pharmaceutical To Pay A Fine
Brief: Oasmia Pharmaceutical Brings Action Against The Former Board Of Directors
Brief: Oasmia Pharmaceutical Appoints Fredrik Järrsten As CFO
Brief: Oasmia Pharmaceutical CFO Resigns
Brief: Capital Conquest Buys 2.6 Million Shares In Oasmia Pharmaceutical
Brief: Oasmia Pharmaceutical Signs Phase 1B Trial Agreement With SAKK
Brief: Oasmia Pharmaceutical Enters Into Settlement Agreement
Brief: Oasmia Pharmaceutical: Outcome Of Strategic Review To Deliver Long-Term, Profitable Growth As A Specialty Pharma Company
Brief: Oasmia Pharmaceutical Q3 Operating Loss Widens To SEK 57.7 Mln
Brief: Oasmia Pharmaceutical And Elevar Sign Partnership Deal